Special Issue Title:

Triple Negative Breast Cancer

Deadline for manuscript submissions: 31 March 2022

Print Special Issue Flyer (1)

Special Issue Editor

  • Guest Editor

    Patrick Neven, MDE-MailWebsite

    Department of Gynecological Oncology, Multidisciplinary Breast Center, Leuven University Hospitals, Herestraat 49, Leuven, Belgium

    Interests: Breast Cancer

Special Issue Information

Dear Colleagues,

Triple negative breast cancer (TNBC) is a heterogeneous disease comprising different orphan breast cancers and defined simply by the absence of ER, PR and HER-2. Approximately 15%-20% of breast cancers exhibit this phenotype, which is characterised by distinct risk factors and molecular features, and a particular clinical presentation and outcome. These features are discussed in the current review. The risk of developing TNBC varies with age, race, genetics, and reproductive factors such as parity and breastfeeding patterns. Loco-regional treatment is often performed after upfront systemic treatment in order to increase breast conservation rates. Similar to other invasive breast cancer subtypes, this involves surgery with or without adjuvant radiotherapy. Some TNBC are very chemo-sensitive and the majority of patients will never relapse. A high density of tumor infiltrating lymphocytes and specific histological subgroups of TNBC can indicate a good prognosis, even in the absence of chemotherapy. Distinct molecular subgroups within TNBC such as the luminal androgen receptor positive subtype have also been defined. 

When metastatic relapse does occur in TNBC cases, it is usually within 3 years of surgery and patient survival following relapse is shorter compared to other breast cancer subtypes. Some new treatment options have proven effective, including the AB-drug conjugate against TROP2, PARP inhibitors in cases of homologous recombination deficiency, and immune checkpoint blockade if there is PD-L1 expression. However, successful treatments remain rare and responses often lack durability. Novel drug targets, new biomarkers and further molecular and biological investigations of TNBC are needed to improve care for breast cancer patients presenting with this subtype. 

This special issue of EJGO on the management of early- and late-stage TNBC serves to update the reader on this important topic.

Prof. Patrick Neven

Guest Editor

Keywords

Triple negative breast cancer

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences